PCI Pharma’s Bedford Facility Passes ICMRA Inspection, First CDMO to Succeed under CHIP Program
PCI Pharma's Bedford site passes ICMRA inspection, first CDMO to succeed under CHIP program.
The International Coalition of Medicines Regulatory Authorities (ICMRA) has successfully concluded its inspection of PCI Pharma Services' (PCI), a worldwide contract development and manufacturing organisation (CDMO) Bedford, New Hampshire site.
By achieving this, PCI becomes the first CDMO for drug
products to successfully pass the multi-agency inspection procedure. This is a
feature of the Collaborative Hybrid Inspection Pilot (CHIP) program, a new
initiative from the ICMRA that focusses on mutual assessment of facilities
within its jurisdiction that manufacture medicines.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Cosette Pharmaceuticals Appoints Andrew Adams as Vice President of Supply Chain and Sourcing
AbbVie Achieves Phase 3 Primary and All Secondary Endpoints for Atogepant in Menstrual Migraine
Discussion